BD introduces first fully absorbable hernia patch

FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm with a market capitalization of $57.39 billion and annual revenue of $20.64 billion, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Phasix™ ST Umbilical Hernia Patch. According to InvestingPro data, BD maintains a strong position in the Healthcare Equipment & Supplies industry, with revenue growing at 5.89% over the last twelve months. This product is the market’s first fully absorbable hernia patch designed specifically for umbilical hernia repairs, marking a significant advancement in surgical options for patients.

The Phasix™ ST Umbilical Hernia Patch is constructed from Poly-4-hydroxybutyrate (P4HB), a biologically-derived material, and features a hydrogel barrier based on Sepra® Technology. It offers a unique absorbable solution to umbilical hernia repair and can be utilized using the same surgical technique as traditional permanent mesh procedures. The patch, which includes a pocket and strap design for optimal placement and fixation, aims to replicate the form and function of the Ventralex™ ST Hernia Patch, a product with a global implantation history of over two million.

General surgeon Dr. Robert Harrell from Live Oak, Texas, expressed his enthusiasm for the new product, highlighting the combination of the Ventralex™ ST Hernia Patch’s features with the bioabsorbable nature of Phasix™ Mesh as a "wonderful fusion of technology."

According to recent survey data, 60% of patients showed a preference for a non-permanent mesh option for hernia repair, and over 70% of surgeons indicated a willingness to accommodate patient preferences for mesh materials. The Phasix™ ST Umbilical Hernia Patch is available in three sizes, catering to a wide range of umbilical soft tissue defects and surgeon requirements for overlap.

BD’s Chief Medical Officer, Ron Silverman, commented on the innovation, stating that BD is "redefining tissue repair through advanced biomaterials" and that the launch of the Phasix™ ST Umbilical Hernia Patch further establishes BD as a leader in biomaterial science and tissue reconstruction.

The Phasix™ ST Umbilical is the latest addition to BD’s Phasix™ Mesh portfolio, which has seen over 385,000 implants worldwide. The portfolio is supported by more than 85 clinical publications, with over 4,000 patients studied, demonstrating proven clinical outcomes.

BD continues to focus on improving medical discovery, diagnostics, and care delivery, with a presence in nearly every country and a commitment to addressing global health challenges. The company’s solid financial health, rated as "GOOD" by InvestingPro analysts, supports its innovation initiatives. Currently trading near its 52-week low, BD shows promising potential, with analysts predicting continued profitability and net income growth this year. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 top US stocks including BD.

In other recent news, BD (Becton, Dickinson and Company) announced the separation of its Biosciences and Diagnostic Solutions business, aiming to enhance strategic focus and shareholder value. This decision follows a comprehensive business portfolio evaluation and is part of BD’s strategy to position itself as a leader in medical technology. Furthermore, BD has commenced a clinical trial for its GalaFLEX LITE™ Scaffold, a device intended to improve outcomes in breast revision surgeries. This trial is a step toward obtaining U.S. FDA Premarket Approval, involving at least 250 patients across multiple sites.

In governance developments, BD appointed Gregory J. Hayes, executive chairman of RTX Corporation, to its board of directors. Hayes is expected to contribute significantly to BD’s strategic transformation. Additionally, BD’s shareholders approved all board nominees at the recent 2025 Annual Meeting, confirming the appointment of Ernst & Young as the independent auditor. In another strategic move, activist investor Starboard Value has acquired a stake in BD, reportedly advocating for the sale of BD’s life sciences division. These recent developments indicate BD’s ongoing efforts to enhance its corporate strategy and operational focus.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.